enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage genetic medicine company developing non-viral gene therapy candidates, with its lead program focused on detalimogene. The company generates no product revenue as of the fiscal year ended October 31, 2025, operating entirely on capital raises, including two PIPE financings completed during FY2024 and a term loan facility with Hercules that carried a senior security interest over substantially all company assets as of October 31, 2025. enGene went public through a business combination agreement dated May 16, 2023, with FEAC, a special purpose acquisition company. Ronald H. W. Cooper serves as Chief Executive Officer and President, with Ryan Daws as Chief Financial Officer, as of December 22, 2025. The company holds an in-license from NTC that requires annual maintenance fees of $50 thousand and provides for milestone and royalty payments upon regulatory approval and product sales. The second milestone, FDA regulatory approval of a covered product, had not been achieved as of October 31, 2025.

Revenue model

No product revenue as of FY2025. The company is pre-commercial and funds operations through equity issuances and debt. It holds an NTC license requiring annual $50 thousand maintenance fees and low-single-digit royalties on future net product sales. Milestone obligations include $450 thousand upon FDA approval of a licensed product, which had not been triggered as of October 31, 2025.

Products and services

Lead clinical program: detalimogene, a gene therapy candidate in development. The company also holds rights under an in-license from NTC covering gene therapy-related patent claims. No commercial products were approved or generating revenue as of October 31, 2025.

Customers and end markets

No commercial customers as of October 31, 2025. End market is genetic medicine and gene therapy for human disease. The company is in clinical-stage development and has not yet sold products to patients, healthcare providers, or payers.

Value-chain role

Clinical-stage drug developer. enGene in-licenses foundational IP from NTC, conducts research and development, and runs clinical trials. It has not yet reached commercial manufacturing or distribution. Hercules holds a senior security interest over substantially all non-IP assets under the Amended Loan Agreement.

Geographic exposure

Operations subject to U.S. and international regulatory requirements including HIPAA, GDPR, and U.K. GDPR. Clinical and business activities span the U.S. and the European Economic Area based on regulatory compliance disclosures in the FY2025 10-K. No specific geographic revenue breakdown is disclosed.

Source: SEC 10-K, filed 2025-12-22

Industry: Biological Products, (No Diagnostic Substances) Peers: ESSA Pharma Inc. Repare Therapeutics Inc. Xenon Pharmaceuticals Inc Zymeworks Inc